EP Patent

EP2310095A1 — Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors

Assigned to Istituto di Ricerche di Biologia Molecolare P Angeletti SpA · Expires 2011-04-20 · 15y expired

What this patent protects

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. Formula (I)

USPTO Abstract

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. Formula (I)

Drugs covered by this patent

Patent Metadata

Patent number
EP2310095A1
Jurisdiction
EP
Classification
—
Expires
2011-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.